UroGen Pharma LtdURGN
Price$40.63

Outlook & Key Dates

Estimates, guidance, catalysts, and upcoming events

Analyst Estimates Learn more →
Analyst Coverage
8analysts covering
Consensus: PositiveAs of 18 Aug 2026
FY EPS (est.)
-$0.24next fiscal year
As of 18 Aug 2026
Monitoring Framework
Key Performance Indicators
ZUSDURI Commercial Revenue Quarterly29.2MTarget: Accelerated adoption post J-code implementation
JELMYTO Net Product Revenue Annually21.7MTarget: 97000000 to 101000000
UGN-103 NDA Submission Timeline QuarterlyTarget: Q3 2026 Submission
Watch Items
  • UGN-103 Regulatory ApprovalTrigger: FDA NDA acceptance and priority review decisionAction: Monitor FDA communications following planned Q3 2026 NDA submission
  • Cash Runway and Operating ExpensesTrigger: Operating expenses exceeding $240M-$250M guidance rangeAction: Evaluate drawdowns on Pharmakon Advisors debt facility or strategic partnerships
Sign in / Sign up to read more

Research as of 19 Jun 2026

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.